Clinical trials: Hepatic Neoplasm
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
The purpose of this study is to characterize the pharmacokinetics (what the body does to the study medication) of JNJ-38518168 at approximately steady-state (stable medication levels) after administration of multiple oral 30 mg…
- Trial name
- NCT01863784
- Testing
- JNJ-38518168
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Janssen Research & Development, LLC
Carcinoma, Hepatocellular
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages.
- Trial name
- NCT01915589
- Testing
- Refametinib (BAY86-9766)
- Where
- 58 sites in United States, Austria and 15 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced…
- Trial name
- PHOCUS (NCT02562755)
- Testing
- Pexastimogene Devacirepvec (Pexa Vec), Sorafenib
- Where
- 142 sites in United States, Australia and 14 more
- Volunteers
- 459 people
- Sponsor
- SillaJen, Inc.
Oncology
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate)…
- Trial name
- NCT02521376
- Testing
- Entospletinib
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Carcinoma, Hepatocellular
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
Primary objective: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV Secondary objective: To evaluate time to progression, 6month…
- Trial name
- NCT00559455
- Testing
- Oxaliplatin, Fluorouracil, Leucovorin
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Sanofi
Carcinoma, Hepatocellular
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
This was a multicenter, randomized, double-blind, phase III trial. This clinical study evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have progressed on Systemic Therapy (Chemotherapy…
- Trial name
- NCT02329860
- Testing
- Apatinib
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths.
- Trial name
- NCT06858813
- Testing
- Lenvatinib, ABBV-324
- Where
- 22 sites in United States, China and 5 more
- Volunteers
- 232 people
- Sponsor
- AbbVie
Advanced Hepatocellular Carcinoma
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of TAC-101 after Transcatheter Arterial Chemoembolization (TACE) in patients with advanced, unresectable hepatocellular carcinoma (HCC) who are being scheduled for…
- Trial name
- NCT00756782
- Testing
- TAC-101
- Sponsor
- Taiho Oncology, Inc.
Malignant Melanoma
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics).
- Trial name
- NCT00145041
- Testing
- Vincristine Sulfate Liposomes Injection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Acrotech Biopharma Inc.
Hepatic Insufficiency, Neoplasms
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
- Trial name
- NCT05209295
- Testing
- Onureg
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 2 people
- Sponsor
- Bristol-Myers Squibb
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with…
- Conditions
- Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
- Trial name
- NCT06682988
- Testing
- Mirvetuximab Soravtansine
- Where
- 52 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- AbbVie
Primary Liver Cancer
cfDNA Methylation for Liver Cancer Recurrence Detection
Through follow-up testing of patients with primary liver cancer who underwent hepatectomy, liver transplantation, ablation therapy, or transarterial chemoembolization (TACE), a blinded comparative trial was conducted at each…
- Trial name
- NCT07466602
- Testing
- plasma GNB4 and Riplet genes methylation detection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Liver Neoplasms, Hepatocellular Carcinoma
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)
This trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.
- Conditions
- Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- #HOPE4LIVER (NCT04573881)
- Testing
- HistoSonics System
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 24 people
- Sponsor
- HistoSonics, Inc.
Carcinoma, Hepatocellular
Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients
Primary: Overall Survival (OS) Secondary: Time to Tumor Progression (TTP) Response Rate (RR) Improvement of Quality of Life (QoL) Safety Secondary resection rate
- Trial name
- EACH (NCT00471965)
- Testing
- Oxaliplatin + 5-Fluorouracil/Leucovorin, Doxorubicin
- Where
- 4 sites in China, South Korea and 2 more
- Volunteers
- 371 people
- Sponsor
- Sanofi
Cancer, Lung, Perfusion Computed Tomography Target Lesion
DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria
DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria. 1. Rationale of the clinical investigation For the evaluation of response to anti-tumoral therapy in thoracic…
- Conditions
- Cancer, Lung, Perfusion Computed Tomography Target Lesion, Cancer Liver, Metastatic Lung Cancer
- Trial name
- NCT04708483
- Testing
- Extra DCE-CT scan
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Hyperfusion
Hepatocellular Carcinoma (HCC)
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable…
- Trial name
- NCT01761266
- Testing
- Lenvatinib, Sorafenib
- Where
- 186 sites in United States, Australia and 19 more
- Volunteers
- 954 people
- Sponsor
- Eisai Limited
Hepatic Malignant Neoplasm Primary Non-Resectable
Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
- Trial name
- NCT03266042
- Where
- 2 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Delcath Systems Inc.
Carcinoma, Hepatocellular
Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety…
- Trial name
- SORINT (NCT01908322)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02839954
- Testing
- anti-MUC1 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Hepatocellular Carcinoma
Chimeric Antigen Receptor T Cells Targeting Glypican-3
A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma
- Trial name
- NCT03884751
- Testing
- CAR-GPC3 T Cells
- Where
- 6 sites in China
- Volunteers
- 9 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.